2013—biotech back in the saddle

Walter Yang

Last year's biotech stocks substantially outperformed the general markets, with the BioCentury 100 and NASDAQ Biotechnology indices showing >25% gains over the S&P 500 and NASDAQ Composite. Excluding partnership monies, a total of \$36.7 billion was raised, on par with 2012. The

Stock market performance

For 2013, the BioCentury 100 gained 59%, while the NASDAQ Biotechnology Index was up 66%.

Global biotech industry financing

Excluding partnerships, biotechs raised \$36.6 billion in 2013, compared with \$36.6 billion in 2012.

Global partnership figures are for deals valued at \$20 million or more. Sources: BCIQ: BioCentury Online Intelligence, Burrill & Co.

Global biotechnology venture capital investment

Private biotechs raised \$5.7 billion in 2013, down from \$6.6 billion in 2012.

	2008	2009	2010	2011	2012	2013
Americas	222	225	243	236	254	268
Europe	113	101	116	117	113	132
Asia-Pacific/Other	7	6	12	15	13	15

Table indicates number of VC investments and includes rounds where the amount raised was not disclosed. Source: BCIQ: BioCentury Online Intelligence

Notable 2013 deals

Company (lead underwriters)	Amount raised (\$ millions)	Change in stock price since offer	Date completed
Ophthotech (Morgan Stanley; JPMorgan)	192	47%	24-Sep
Intrexon (JPMorgan; Barclays)	184	49%	8-Aug
PTC Therapeutics (JPMorgan; Credit Suisse)	144	13%	20-Jun
Portola (Morgan Stanley; Credit Suisse)	140	78%	22-May
Karyopharm (BofA Merrill Lynch; Leerink Swann)	125	43%	5-Nov
Agios (JPMorgan; Goldman Sachs)	122	33%	23-Jul
Chimerix (Morgan Stanley; Cowen)	118	8%	11-Apr
bluebird bio (JPMorgan; BofA Merrill Lynch)	116	23%	18-Jun

first IPO window since 2007 brought in \$3.8 billion, up 168% from 2012; follow-on offerings (\$10 billion) were also up 58% from 2012; but debt deals were down from 2012's \$19.6 billion. Private company fundraising came in at around the 2008–2012 annual average of \$5.5 billion.

Global biotech initial public offerings

59 companies raised \$3.8 billion via IPOs in 2013 compared with the 2008–2012 annual average of \$963 million.

	2008	2009	2010	2011	2012	2013
Americas	1	4	18	11	12	41
Europe	3	3	10	4	7	9
Asia-Pacific	2	3	5	8	6	9

Table indicates number of IPOs. Source: BCIQ: BioCentury Online Intelligence

Notable 2013 deals (continued)

Company (lead investors)	Amount raised (\$ millions)	Round number	Date closed
Intrexon (not disclosed)	150	6	1-May
Juno (Arch Venture; Crestline)	120	1	4-Dec
Moderna (Flagship Ventures)	110	ND	20-Nov
Oxford Nanopore ^a	64	ND	9-Oct
Ganymed (ATS Beteiligungsverwaltung; MIG Funds; FCPB Gany)	61	5	18-Nov
Dicerna (RA Capital)	60	3	1-Aug
PTC Therapeutics (Brookside Capital)	60	ND	7-Mar
Trevena (Forest Laboratories)	60	3	9-May

Mergers and acquisitions

Target	Acquirer	Value ^{b,c} (\$ millions)	Date announced
Onyx	Amgen	10,400	25-Aug
Elan	Perrigo	9,200	29-Jul
Warner Chilcott	Actavis	5,785	1-Oct
ViroPharma	Shire	4,200	11-Nov
Algeta	Bayer	2,900	19-Dec
Santarus	Salix	2,600	7-Nov

Licensing/collaboration

Researcher	Licensee	Value ^b (\$ millions)	Deal description
OncoMed	Celgene	3,327	Options to jointly develop six of cancer stem cell products/ small molecules
Pfizer	Eli Lilly	1,780	Jointly develop and globally commercialize tanezumab in phase 2 pain trial
Molecular Partners	Roche	1,160	Generate conjugates of toxic agents with designed ankyrin repeat proteins (DARPs) in cancer
MacroGenics	Gilead	1,115	Develop preclinical bispecific diabody scaffolds against up to four targets
Immatics bio-technologies	Roche	1,017	Develop cancer vaccines and immunotherapies containing tumor-associated peptides

^aLead investor not disclosed. ^bValues include milestones. ^cIf deal closed, value is at time of completion. Source: BCIQ: BioCentury Online Intelligence

Walter Yang is Research Director at BioCentury.